Text Size

Hepatic Impairment Study

This study has been completed.
Sponsor:
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT00829231
First received: January 23, 2009
Last updated: October 30, 2012
Last verified: October 2012
History of Changes
  Purpose

This study is to find out how the subject's body processes and reacts to the study drug, and to find out how long it remains in the subjects system after one dose. Subjects with varying degrees of liver function are being asked to participate in this study. Study results from subjects with normal liver function will be compared with study results from subjects with impaired liver function.


Condition Intervention Phase
Liver Disease
 Drug: Sorafenib (Nexavar, BAY43-9006)
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Label, Phase 1 to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetic of Sorafenib ( BAY43-9006)

Resource links provided by NLM:

MedlinePlus related topics: Liver Diseases
U.S. FDA Resources

Further study details as provided by Bayer:

Primary Outcome Measures:
  • PK measurements [ Time Frame: Day 1-6 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Physical Exam [ Time Frame: Screening, Day 6 ] [ Designated as safety issue: Yes ]
  • Labotatory Safety, Chemistry panel, PTT, hematology Urine Analysis [ Time Frame: Screening Day 1, Day 6 ] [ Designated as safety issue: Yes ]
  • ECG [ Time Frame: Screening Day 1, Day 6 ] [ Designated as safety issue: Yes ]
  • Vital Signs [ Time Frame: Screening Day 1, Day 6 ] [ Designated as safety issue: Yes ]
  • Follow up phone call [ Time Frame: Day 14 ] [ Designated as safety issue: Yes ]

Enrollment: 45
Study Start Date: January 2009
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Sorafenib (Nexavar, BAY43-9006)
Mildly Hepatic Impaired Subjects
Experimental: Arm 2 Drug: Sorafenib (Nexavar, BAY43-9006)
Moderately Hepatic Impaired Subjects
Experimental: Arm 3 Drug: Sorafenib (Nexavar, BAY43-9006)
Healthy Subjects

  Eligibility

Ages Eligible for Study:   50 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy Subjects, Child Pugh A and Child Pugh B Liver Disease Patients.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00829231

Locations
United States, Florida
Miami, Florida, United States, 33014
Orlando, Florida, United States, 32809
United States, Tennessee
Knoxville, Tennessee, United States, 37920
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Click here and search for drug information provided by the FDA.  This link exits the ClinicalTrials.gov site
Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.  This link exits the ClinicalTrials.gov site
Click here to find results for studies related to Bayer Healthcare products.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Head Clinical Pharmacology, Bayer Healthcare Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT00829231     History of Changes
Other Study ID Numbers: 12349
Study First Received: January 23, 2009
Last Updated: October 30, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Bayer:
Liver disease

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases
Sorafenib
Antineoplastic Agents
Therapeutic Uses
 Pharmacologic Actions
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 23, 2013